Yield10 Bioscience
YTEN
Revenue for Yield10 Bioscience (YTEN)
Revenue in 2023 (TTM): $0.12 M
According to Yield10 Bioscience's latest financial reports the company's current revenue (TTM
) is $0.12 M.
In 2022 the company made a revenue of $0.33 M a decrease over the years 2021 revenue that were of $0.61 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Yield10 Bioscience from 2004 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.12 M | -64.6% |
| 2022 | $0.33 M | -44.79% |
| 2021 | $0.61 M | -23.15% |
| 2020 | $0.79 M | -0.87% |
| 2019 | $0.8 M | 44.96% |
| 2018 | $0.55 M | -41.1% |
| 2017 | $0.94 M | -18.55% |
| 2016 | $1.15 M | -47.6% |
| 2015 | $2.21 M | -21% |
| 2014 | $2.8 M | -45.82% |
| 2013 | $5.16 M | -87.79% |
| 2012 | $42.31 M | 2869.54% |
| 2011 | $1.42 M | 218.08% |
| 2010 | $0.44 M | -68.56% |
| 2009 | $1.42 M | -8.36% |
| 2008 | $1.55 M | -7.66% |
| 2007 | $1.68 M | -63.3% |
| 2006 | $4.58 M | 65.01% |
| 2005 | $2.78 M | -24.39% |
| 2004 | $3.67 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
 NRC Health
NRC | $0.14 B | 123,716.67% | 🇺🇸 USA |